Form 4: Cytokinetics Director Lynne Parshall Reports Stock Transactions
SEC Form 4 Filing
Director Lynne Parshall reported the acquisition and disposal of Cytokinetics Inc. common stock and stock options on May 15, 2024.
Summary
- On May 15, 2024, Lynne Parshall, a director of Cytokinetics Inc., reported transactions involving the company's stock.
- Parshall acquired 5,600 shares of common stock.
- Parshall also acquired 3,636 non-qualified stock options with an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
- Following these transactions, Parshall directly owns 20,600 shares of common stock and 3,636 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company director, indicating neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of earliest transaction: Acquisition and disposal of common stock and acquisition of stock options. |
| 05/15/2034 | Expiration date of the non-qualified stock options. |
| 06/17/2024 | Date the non-qualified stock options become exercisable. |
| 05/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.